Sotac PharmaceuticalsNSE:SOTAC 53 EBITDA Margin % is 21.42% as of Sep. 2025, which is 158% above its 10-year median of 8.30. GuruFocus rates NSE:SOTAC with a GF Score™ of 53/100 and a GF Value™ of ₹110.01 (Fairly Valued). The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Sotac Pharmaceuticals ranks better than 77.8% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sotac Pharmaceuticals EBITDA Margin % Related Terms
Sotac Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sotac Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sotac Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotac Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sotac Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sotac Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotac Pharmaceuticals (NSE:SOTAC) has a EBITDA Margin % of 21.42% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sotac Pharmaceuticals and its competitors. This is 158% above median its historical median of 8.30. Over the past decade, Sotac Pharmaceuticals' EBITDA Margin % has ranged from 3.14 to 24.69. According to the industry distribution chart, Sotac Pharmaceuticals ranks #212 out of 955 companies in the Drug Manufacturers industry, placing it in the top 22.2%.
Is Sotac Pharmaceuticals' EBITDA Margin % too high?
Sotac Pharmaceuticals' current EBITDA Margin % of 21.42% is 158% above median its 10-year median of 8.30. Over the past 10 years, this metric has ranged from a low of 3.14 to a high of 24.69. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Sotac Pharmaceuticals' value of 21.42% is 72.2% above this industry median. Based on the distribution chart, Sotac Pharmaceuticals ranks #212 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sotac Pharmaceuticals has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sotac Pharmaceuticals ranks #212 out of 955 companies for EBITDA Margin %. This places Sotac Pharmaceuticals in the top 22% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Sotac Pharmaceuticals' value of 21.42% is 72.2% above this benchmark. Historically, Sotac Pharmaceuticals' own EBITDA Margin % has ranged from 3.14 to 24.69 over the past decade. While the company's 10-year median is 8.30 vs. the industry median of 12.44, Sotac Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotac Pharmaceuticals's current EBITDA Margin % of 21.42% is 72.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sotac Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotac Pharmaceuticals's current EBITDA Margin % is 21.42%, which is 158% above median its own 10-year median of 8.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Fairly Valued. The stock's GF Value™ is ₹110.01, compared to a current price of ₹105.00 — trading 4.6% below its estimated fair value. The current EBITDA Margin % is 21.42%, which is 158% above median its 10-year median of 8.30 and 72.2% above the Drug Manufacturers industry median of 12.44. Sotac Pharmaceuticals' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current EBITDA Margin % is 21.42% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹105.00 is trading 4.6% below its estimated GF Value™ of ₹110.01.
GuruFocus considers Sotac Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:SOTAC:
EBITDA Margin %: 21.42% (158% above median its 10-year median of 8.30)
GF Value™: ₹110.01 vs. price of ₹105.00 (4.6% below fair value)
Industry Position: 72.2% above the Drug Manufacturers median (#212 of 955)
No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
53GF Score
Get the complete analysis for NSE:SOTAC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOTAC has been successfully added to your 
